p16 Deletion in sarcomatoid tumors of the lung and pleura.
about
MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.Overview of the biochemical and genetic processes in malignant mesothelioma.Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine.The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.A case of intracranial solitary fibrous tumor/hemangiopericytoma with dedifferentiated component.
P2860
p16 Deletion in sarcomatoid tumors of the lung and pleura.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
p16 Deletion in sarcomatoid tumors of the lung and pleura.
@en
p16 Deletion in sarcomatoid tumors of the lung and pleura.
@nl
type
label
p16 Deletion in sarcomatoid tumors of the lung and pleura.
@en
p16 Deletion in sarcomatoid tumors of the lung and pleura.
@nl
prefLabel
p16 Deletion in sarcomatoid tumors of the lung and pleura.
@en
p16 Deletion in sarcomatoid tumors of the lung and pleura.
@nl
P2093
P1476
p16 Deletion in sarcomatoid tumors of the lung and pleura.
@en
P2093
Lucian R Chirieac
Naobumi Tochigi
Philip T Cagle
Richard Attanoos
Sanja Dacic
Timothy Craig Allen
P304
P356
10.5858/ARPA.2012-0108-OA
P577
2013-05-01T00:00:00Z